Pam K. Mangat

1.1k total citations
47 papers, 644 citations indexed

About

Pam K. Mangat is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Pam K. Mangat has authored 47 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Pam K. Mangat's work include Lung Cancer Treatments and Mutations (16 papers), Advanced Breast Cancer Therapies (14 papers) and Colorectal Cancer Treatments and Studies (13 papers). Pam K. Mangat is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Advanced Breast Cancer Therapies (14 papers) and Colorectal Cancer Treatments and Studies (13 papers). Pam K. Mangat collaborates with scholars based in United States. Pam K. Mangat's co-authors include Elizabeth Garrett‐Mayer, Richard L. Schilsky, Susan Halabi, Eugene R. Ahn, Suanna S. Bruinooge, Andrew L. Rygiel, Kaitlyn R. Antonelli, Kathleen J. Yost, Ajjai Alva and Timothy Lewis Cannon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Pam K. Mangat

43 papers receiving 641 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pam K. Mangat United States	12	468	322	273	140	99	47	644
Amy Krie United States	5	257 0.5×	268 0.8×	172 0.6×	172 1.2×	80 0.8×	10	527
Tareq Al Baghdadi United States	12	415 0.9×	175 0.5×	217 0.8×	196 1.4×	61 0.6×	35	593
Soma Ghosh United States	8	455 1.0×	205 0.6×	234 0.9×	185 1.3×	73 0.7×	12	660
Patricia Gómez Spain	8	486 1.0×	257 0.8×	182 0.7×	155 1.1×	36 0.4×	16	653
Nancy G. Iskander United States	3	218 0.5×	295 0.9×	199 0.7×	116 0.8×	83 0.8×	5	429
David Mallery United States	4	247 0.5×	329 1.0×	212 0.8×	130 0.9×	87 0.9×	5	498
Christoph Petry Germany	13	474 1.0×	747 2.3×	205 0.8×	253 1.8×	118 1.2×	33	952
Lisette Stork‐Sloots United States	13	399 0.9×	451 1.4×	94 0.3×	148 1.1×	159 1.6×	49	633
Mizue Krygowski United States	10	360 0.8×	343 1.1×	659 2.4×	640 4.6×	45 0.5×	13	992
Fabian Zohren United States	14	288 0.6×	230 0.7×	690 2.5×	331 2.4×	63 0.6×	44	1.1k

Countries citing papers authored by Pam K. Mangat

Since Specialization

Citations

This map shows the geographic impact of Pam K. Mangat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pam K. Mangat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pam K. Mangat more than expected).

Fields of papers citing papers by Pam K. Mangat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pam K. Mangat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pam K. Mangat. The network helps show where Pam K. Mangat may publish in the future.

Co-authorship network of co-authors of Pam K. Mangat

This figure shows the co-authorship network connecting the top 25 collaborators of Pam K. Mangat. A scholar is included among the top collaborators of Pam K. Mangat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pam K. Mangat. Pam K. Mangat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Veljovich, Dan S., Michael Rothe, Pam K. Mangat, et al.. (2025). Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 43(16_suppl).

Mangat, Pam K., M. Kelsey Kirkwood, Dominique C. Hinshaw, Elizabeth Garrett‐Mayer, & Richard L. Schilsky. (2025). Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. npj Precision Oncology. 9(1). 222–222. 1 indexed citations

Rodón, Jordi, Michael Rothe, Pam K. Mangat, et al.. (2025). Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. ESMO Open. 10(5). 104545–104545. 3 indexed citations

Srkalović, Gordan, Michael Rothe, Pam K. Mangat, et al.. (2024). Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 8(8). e2400026–e2400026. 1 indexed citations

Ahn, Eugene R., Michael Rothe, Pam K. Mangat, et al.. (2024). Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 1 indexed citations

Schuetze, Scott M., Michael Rothe, Pam K. Mangat, et al.. (2024). Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 8(8). e2400219–e2400219. 2 indexed citations

Sahai, Vaibhav, Michael Rothe, Pam K. Mangat, et al.. (2024). Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 8(8). e2300527–e2300527.

Rothe, Michael, et al.. (2024). Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precision Oncology. 8(8). e2300615–e2300615. 1 indexed citations

Yost, Kathleen J., Michael Rothe, Pam K. Mangat, et al.. (2024). Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 42(3_suppl). 106–106. 1 indexed citations

10.

Ganti, Apar Kishor, Michael Rothe, Pam K. Mangat, et al.. (2023). Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 7(7). e2300041–e2300041. 6 indexed citations

11.

Srkalović, Gordan, Michael Rothe, Pam K. Mangat, et al.. (2023). Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(16_suppl). 3115–3115.

12.

Mileham, Kathryn F., Michael Rothe, Pam K. Mangat, et al.. (2023). Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 83(8_Supplement). CT226–CT226. 1 indexed citations

13.

Ahn, Eugene R., Michael Rothe, Pam K. Mangat, et al.. (2023). Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precision Oncology. 7(7). e2200609–e2200609. 12 indexed citations

14.

Khalil, M.F., Michael Rothe, Pam K. Mangat, et al.. (2023). 207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. 34. S265–S266. 1 indexed citations

15.

Klute, Kelsey, Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2022). Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer WithBRAFMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 6(6). e2200191–e2200191. 16 indexed citations

16.

Mangat, Pam K., Elizabeth Garrett‐Mayer, Elie G. Dib, et al.. (2022). 978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. 33. S997–S998. 1 indexed citations

17.

Fisher, Julie Gottlieb, David L. Tait, Elizabeth Garrett‐Mayer, et al.. (2020). Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology. 15(6). 733–741. 30 indexed citations

18.

Baghdadi, Tareq Al, Elizabeth Garrett‐Mayer, Susan Halabi, et al.. (2020). Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology. 15(6). 743–750. 26 indexed citations

19.

Baghdadi, Tareq Al, Susan Halabi, Elizabeth Garrett‐Mayer, et al.. (2019). Palbociclib in Patients With Pancreatic and Biliary Cancer WithCDKN2AAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 3(3). 1–8. 66 indexed citations

20.

Álvarez, Ricardo H., Elizabeth Garrett‐Mayer, Susan Halabi, et al.. (2019). Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) with FLT-3 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 79(13_Supplement). CT146–CT146. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact